Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_1

Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma

NCT06751134
recruitingphase_1

Universal CNK-UT Therapy for Refractory aGVHD

NCT06750133
recruitingphase_1

Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD

NCT06568328

Clinical Trials (3)

Showing 3 of 3 trials
NCT06751134Phase 1

Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma

Recruiting
NCT06750133Phase 1

Universal CNK-UT Therapy for Refractory aGVHD

Recruiting
NCT06568328Phase 1

Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3